A post on in-pharmatechnologist.com summarizes a report by Moody’s forecasting that pharmaceutical companies in the United States and Europe will face difficult times over the course of the next 12-18 months.
Some of the causes identified by Moody’s include:
- patent expirations and challenges to existing patents;
- difficult regulatory climate;
- downward pricing pressures; and
- unexpected problems related to product safety.